Summary of Medical Aesthetics Industry Conference Call Industry Overview - The medical aesthetics industry is experiencing a slowdown in overall revenue growth, with August showing a 4% increase, influenced by a rise in non-surgical procedures and price transparency leading to a significant drop in average transaction value [1][3] - The average transaction value in July decreased by 5% year-on-year to approximately 3,300 RMB, marking the lowest in recent years. Although it slightly rebounded to around 3,600 RMB in August, it remains below last year's levels [1][4] Key Insights - Major industry players such as Langzi, Yixin, and Liga are facing disappointing revenue growth, with Yixin's retail sales remaining flat in July and August, and some months even showing declines [1][6] - The decline in average transaction value is attributed to increased price transparency, a higher proportion of non-surgical light medical aesthetics projects, and price wars initiated by platforms like Xinyang, which offer low-priced services [1][7] - Medical aesthetics institutions are actively expanding their light medical aesthetics sub-brands, focusing on skin light therapy, injections, and minimally invasive procedures. These smaller stores (500-1,000 square meters) are expanding slowly (3-5 new stores per year) but are expected to be a key growth area due to lower investment and easier scalability [1][9] Operational Differences - Traditional large medical aesthetics institutions and light medical aesthetics stores differ significantly in terms of investment, size, location, revenue, and return cycles. Light medical aesthetics stores require lower initial investments (5-6 million RMB) and have shorter return periods (6 months to break even, 8-10 months to profitability) but operate at lower profit margins [1][10][11] Market Trends - The high-end imported hyaluronic acid products like Juvederm and Restylane are seeing declining sales, with institutions opting for OEM products to reduce procurement costs. Newer domestic products like Gege Needle and Bobo Needle are performing well, compensating for the price drops of traditional brands [1][4][16][17] - The overall market for regenerative collagen products is growing, with Shuyancui emerging as a new growth point, driving market development despite some traditional products experiencing declines [1][19][20] Future Outlook - The industry anticipates continued declines in average transaction value and sluggish revenue growth. However, positive customer traffic growth is expected, prompting institutions to implement more promotional activities and focus on high-margin product lines [1][8] - The medical aesthetics sector typically sees a peak in September and October, with a projected 15% year-on-year growth target for September 2025. Operators plan to boost revenue through repeat purchases and promotional activities [1][15] Product Performance - The sales performance of core products in July and August indicates a decline in high-end imported hyaluronic acid sales, while new injection products are gaining traction. For instance, the sales of the HiTi series from Aimeike dropped significantly, while new products like Gege Needle and Bobo Needle are seeing increased usage [1][18][21] - The overall growth rate for injection collagen products is around 17%, with specific products like Wei Yimei showing a remarkable 45% increase compared to the previous year [1][21] Pricing and Cost Dynamics - Upstream manufacturers have reduced ex-factory prices by approximately 20%-30%, impacting the competitive landscape and prompting institutions to adapt by switching brands to maintain competitiveness [1][26]

Summary of the Conference Call for Xinyang Industry Overview - The medical aesthetics industry is characterized by a single-store profit margin of approximately 10% for mature institutions. Xinyang focuses on the anti-aging sector, reducing service product units (SPU), and targeting middle-class consumers with an average spending of over 2,000 yuan to meet annual anti-aging needs [2][4]. Key Points and Arguments - **Profitability Enhancement**: Xinyang aims to improve profitability through economies of scale and reduced customer acquisition costs. The user referral rate is increasing, which helps maintain low acquisition costs. Mature stores in first-tier cities have profit margins of about 10% to 15%, while stores in the ramp-up phase achieve around 10% net profit margin [2][6]. - **Supply Chain Strategy**: The company plans to increase its self-supply ratio from the current 15% to 30%-40% within the next three to four years, significantly lowering material costs. This is part of a broader strategy to enhance profit margins by controlling supply chain costs [7][8]. - **Store Expansion Plans**: Xinyang plans to open 50 stores by the end of 2025, primarily in first- and second-tier cities, with a focus on direct management and exploring a fully managed franchise model. By 2026, the company expects to open at least 30 more stores, bringing the total to over 80 [4][19]. - **Cost Structure**: In mature medical aesthetic institutions in first-tier cities, material costs account for about 45% of revenue, while labor costs (including doctors, nurses, and managers) range from 25% to 27%. Marketing costs stabilize around 10% after a year of operation [3][10]. - **Market Positioning**: Xinyang targets middle-class consumers with annual spending on aesthetic treatments between 10,000 to 20,000 yuan. The company aims to encourage 4 to 6 treatments per year to cover annual anti-aging needs [5][24]. - **Customer Retention and Product Strategy**: The company focuses on educating users about domestic products that offer similar quality at lower prices. This strategy is expected to help retain existing customers and attract new ones [12][24]. - **Profit Margin Goals**: Xinyang is confident in achieving a net profit margin of 20% in the long term, especially after increasing the self-supply ratio [24]. Additional Important Insights - **Challenges in Expansion**: The medical aesthetics industry faces challenges such as regional differences and reliance on high-quality store managers. Xinyang is addressing this through digital management to reduce dependence on high-salary managers [16][17]. - **Competitive Landscape**: The company believes its model is difficult to replicate due to its comprehensive system and established brand presence, which creates a flywheel effect for customer acquisition [18]. - **Performance in Second-Tier Cities**: Xinyang is testing its operational model in second-tier cities, with plans to open new stores and validate its approach based on experiences from first-tier cities [15][22]. - **Customer Spending Trends**: There has been a 20% increase in average spending per visit from existing customers in 2025, indicating a positive trend in customer engagement [23]. - **Future Strategic Focus**: The company will continue to prioritize offline chain operations, recognizing that the medical aesthetics sector requires a slower expansion pace compared to other industries like fast food [26]. This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Xinyang's focus on profitability, supply chain management, and market positioning within the medical aesthetics industry.

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [2]. Core Insights - In Q2 2025, the company's beauty treatment revenue exceeded guidance, with over 70% of new customers acquired through private channels and referrals [5]. - The company reported total revenue of 378.7 million yuan, a year-on-year decrease of 7.0%, and a net loss of 36 million yuan compared to a net profit of 18.9 million yuan in the same period last year [5]. - The beauty treatment service revenue reached 144.4 million yuan, surpassing the previous guidance of 120-140 million yuan, with a year-on-year growth of 426.1% driven by the expansion of beauty centers [5]. - The company anticipates Q3 2025 beauty treatment service revenue to be between 150-170 million yuan, representing a year-on-year growth of 230.5% to 274.6% [5]. - The company plans to expand its beauty center network to 50 locations by the end of the year, with over 70% of new customers coming from private channels and referrals, resulting in a low customer acquisition cost [5]. Financial Summary - The company forecasts revenues of 1.567 billion yuan, 2.751 billion yuan, and 4.366 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 7%, 76%, and 59% [7]. - The projected net profit for 2025 is a loss of 148 million yuan, followed by profits of 36 million yuan and 134 million yuan in 2026 and 2027, reflecting year-on-year growth rates of 75% and 124% [7]. - The report indicates a significant improvement in gross margin for the beauty treatment business, reaching 24.25% in Q2 2025, an increase of 5.5 percentage points quarter-on-quarter [5].

Core Viewpoint - The company is optimistic about the growth potential of the Chinese medical beauty market, which currently has a penetration rate of less than 5%, compared to over 20% in mature markets like South Korea [1][2] Group 1: Business Transition - The company has shifted its business model from being a transaction intermediary to directly opening offline medical beauty stores, which may lead to competition with its existing clients [1][2] - The opening of offline stores has resulted in a significant conflict between new and old business lines, leading to a decline in the number of service providers subscribing to the platform [2] Group 2: Financial Performance - In the first half of 2025, the company's revenue was 676 million yuan, a decrease of 6.9% from 726 million yuan in the same period last year, with a net loss of 67.95 million yuan compared to a net loss of 600,000 yuan in the previous year [2] - The company's offline business has now surpassed its online business, becoming the largest source of revenue, with revenue from beauty treatment services reaching 144.4 million yuan, a year-on-year increase of 426.1% [3] Group 3: Future Plans - The company plans to open 50 offline stores nationwide this year, with a goal of achieving a thousand-store scale within 8 to 10 years [3] - Despite the challenges, the company believes that the growth of its chain business will offset the decline in traditional business in the long term [3]

8月25日，新氧(SY)盘中上涨5.19%，截至21:35，报4.26美元/股，成交113.36万美元，总市值4.23亿美 元。 资料显示，新氧国际公司是一家致力于用科技的方式帮助爱美女性健康变美的公司。创始人成立了新 氧,通过提供透明的信息,改变中国快速增长但不透明的医学美学市场,最终使他们能够建立一个一站式的 平台,用户可以方便地找到优质的服务。 本文源自：金融界 作者：行情君 财务数据显示，截至2025年06月30日，新氧收入总额6.76亿人民币，同比减少6.84%；归母净利 润-6917.7万人民币，同比减少2909.0%。 大事提醒： 8月19日，新氧获海通国际维持评级至增持，目标价上调至10.3美元。 ...

Summary of the Conference Call Industry Overview - The light medical beauty industry is transitioning from reliance on high-priced projects and well-known doctors to standardized, cost-effective services. New Oxygen focuses on dermatology and small store layouts to meet consumer demands for transparency in product ingredients and pricing [2][4][18]. - The competition in the upstream product market for medical beauty is intensifying, with a significant increase in the issuance of three types of certificates in China. It is expected that by 2026, more companies will launch alternative products, breaking the monopoly of a few high-priced products and leading to market scaling [2][6][7]. Company Strategy and Operations - Traditional medical beauty institutions face high marketing costs and limited profit margins. New Oxygen aims to improve profit margins by controlling marketing costs, optimizing the supply chain, and developing proprietary products. The company is also exploring a model of self-operated small clinics [2][8][9]. - The chain rate in the light medical beauty industry is expected to increase, but it requires the provision of standardized treatments and high cost-performance services. New Oxygen implements a hard discount model to maintain profit margins while offering cost-effective services [2][10]. - The operational efficiency of chain clinics is influenced by scale, density, and efficiency. New Oxygen adopts a strategy that balances breadth and depth, focusing on high-density layouts in key cities to highlight chain advantages and improve overall efficiency [2][11]. Market Dynamics - The Chinese medical beauty market has developed rapidly over the past few years, but the industry chain structure still leans towards a seller's market with low chain rates. New Oxygen recognizes the challenges and pain points in the development of medical beauty chains and plans to leverage its advantages to achieve growth [3][8]. - The rise of regenerative products like water light needles and botulinum toxin has increased the proportion of dermatology projects, which are characterized by high frequency, low risk, and suitability for small chain stores [4][5]. Financial Performance and Projections - Traditional medical beauty institutions have low profit margins, with some large institutions only achieving around 3% to 5%. Marketing costs account for 30% to 50%, along with 20% to 30% for product costs. New Oxygen aims to control marketing costs within 10% and reduce product costs through its supply chain [8][9][22]. - Currently, the net profit margin for New Oxygen's stores is approximately 10% to 15%. In the next two to three years, as the proportion of proprietary products increases, the company expects the net profit margin to rise to 15% or even 20% [22]. Customer Retention and Cost Management - New Oxygen's model leans towards benefiting consumers and achieving equity in medical beauty services. The company employs various strategies to enhance customer retention and meet the needs of price-sensitive consumers, including membership operations, promotional activities, and community engagement [18][19]. - The company maintains a cost advantage in customer acquisition primarily through user referrals and private domain operations, which account for nearly 70% of its customer acquisition strategy [21]. Future Outlook - The light medical beauty industry is naturally suited for chain penetration due to its high standardization. New Oxygen plans to expand its presence in key cities with high-density layouts to leverage chain advantages [10][11]. - The company is also testing different site selection strategies for new clinics, focusing on core business districts and popular shopping centers to optimize overall operational effectiveness [14][16]. Conclusion - New Oxygen is strategically positioned to capitalize on the evolving landscape of the light medical beauty industry by focusing on cost-effective services, optimizing supply chains, and enhancing customer engagement. The company's proactive approach to market dynamics and operational efficiency is expected to drive future growth and profitability [2][10][21].

Group 1 - The core viewpoint of the article highlights the positive performance of various companies in the Hong Kong stock market, with significant profit growth and strategic initiatives such as share buybacks and financing rounds [1][2][3][4]. Group 2 - 万国数据-SW (09698) reported a profit of 690 million RMB for the first half of the year, marking a turnaround from losses, and is currently pursuing a Series C financing round to support future projects [1]. - BOSS直聘-W (02076) saw a 85% increase in net profit year-on-year, with a nearly 20% rise in average monthly active users, and announced a share buyback plan of up to 250 million USD [1]. - 长城汽车 (02333) experienced a nearly 6% increase in stock price, with over 20,000 orders for the Haval Menglong 2026 model within 24 hours, indicating strong demand and potential for profit growth [1]. - 周生生 (00116) anticipates a mid-term profit increase to over 900 million RMB, driven by rising gold prices and effective cost control measures [1]. - 中国中车 (01766) saw a stock price increase of over 5% due to the successful bidding for 210 sets of trains, with expectations of sustained high railway investment [2]. - 中广核矿业 (01164) issued a profit warning, expecting a mid-term loss of up to 90 million HKD due to significant price fluctuations in uranium trading [2]. - 特步国际 (01368) reported better-than-expected performance, with a 12% higher net profit than Goldman Sachs' forecast, attributed to increased other income and revenue [2]. - 中国联通 (00762) experienced a stock price increase of over 4%, with expectations of stable dividend growth despite mid-term performance pressures [2]. - 玖龙纸业 (02689) anticipates a maximum annual profit growth of 190%, driven by declining costs [2]. - 海丰国际 (01308) reported a nearly 80% increase in net profit for the first half of the year, attributed to a 7.3% increase in container volume and a 22.8% rise in average freight rates [3].

目前，轻医美连锁品牌"新氧青春诊所"医美门店数量增至33家。新氧董事长兼CEO金星表示，公司未来 会加大新氧青春诊所在北京、广深等地的密度，预计今年门店数达到50家。 新氧(SY.US)收涨9.43%，报4.06美元，总市值4.03亿美元。新氧2025年第二季度财报显示，二季度公司 实现总收入3.79亿元。其中，线下轻医美业务增长迅猛，医美诊疗服务营收为1.44亿元，同比增速达 426.1%；这一数字首次超越其他业务板块，成为公司最大的收入来源。 ...

Summary of the Conference Call for Xinyang Company Overview - **Company**: Xinyang - **Industry**: Medical Aesthetics Key Points and Arguments Financial Performance - In Q2, Xinyang recorded 67,000 service transactions and 155,000 treatment projects, with over 100,000 active users, indicating strong user engagement [2][3] - Despite an increase in net profit loss, revenue from the chain business grew by 46% quarter-over-quarter, reflecting improved operational efficiency [2][5] - The net profit loss in Q2 was primarily due to overspending in upstream and platform operations, with a total operational loss of approximately 3 million yuan more than Q1 [5] Business Strategy - Xinyang's strategy focuses on expanding its chain business in major cities while optimizing operational costs and improving efficiency [4][13] - The company plans to streamline its POP business and reduce SKUs to enhance consumer decision-making in selecting medical aesthetic institutions [20] - Xinyang aims to maintain a balance between short-term capital investment and long-term strategy by controlling costs and ensuring the chain business achieves profitability [5][23] Market Position and User Demographics - The core target demographic for Xinyang is middle-class middle-aged women, primarily seeking light medical aesthetic anti-aging services [2][8] - The company is exploring new service categories, such as nutritional drip projects, leveraging its existing user base to minimize marketing costs [8] Competitive Advantage - Xinyang employs a high-low product strategy, offering both proprietary and mainstream market products to build consumer trust and gradually shift users to its own products [9][10] - The company has successfully positioned its products, such as Fortinasti, as cost-effective alternatives to mainstream offerings [10] Growth Potential - Despite Q3 typically being a slow season for the medical aesthetics industry, Xinyang's chain business continues to show high growth, primarily driven by existing stores [11] - The company is focused on increasing the proportion of core hero products in its service offerings, which currently stands at over 30% [5] Supply Chain and Product Development - Xinyang has signed contracts with new upstream suppliers to significantly reduce product procurement costs, enhancing gross margins [7] - The company anticipates that self-developed products, such as the three-category water light and future products, will further reduce costs and increase profit margins [7] Expansion Strategy - Xinyang's expansion strategy in first-tier cities involves increasing store density in key shopping areas to lower customer acquisition and operational costs [4][13] - The company plans to adopt a saturation attack strategy in second-tier cities, expanding its presence to enhance operational advantages and brand effect [16] Operational Efficiency - The operational model of Xinyang differs from traditional medical aesthetic institutions, relying on a strong central management system to streamline operations across multiple locations [19] - The company expects mature stores in first-tier cities to achieve monthly revenue of 7,000 yuan per square meter, with potential for higher performance in select locations [24][27] Future Outlook - Xinyang's cash reserves are currently sufficient to support future expansion without immediate plans for refinancing [23] - The company is optimistic about further improving revenue per square meter through flexible pricing strategies and new product launches [27] Additional Important Insights - The medical aesthetics industry allows for premium pricing as customer willingness to pay for quality treatments remains high [3][6] - Xinyang's focus on user retention and satisfaction metrics, such as repurchase rates and active user counts, is critical for long-term success [3][5]

财务数据显示，截至2025年06月30日，新氧收入总额6.76亿人民币，同比减少6.84%；归母净利 润-6917.7万人民币，同比减少2909.0%。 大事提醒： 8月20日，新氧(SY)开盘上涨5.12%，截至21:33，报3.9美元/股，成交42.09万美元，总市值3.87亿美元。 8月19日，新氧获海通国际维持评级至增持，目标价上调至10.3美元。 资料显示，新氧国际公司是一家致力于用科技的方式帮助爱美女性健康变美的公司。创始人成立了新 氧,通过提供透明的信息,改变中国快速增长但不透明的医学美学市场,最终使他们能够建立一个一站式的 平台,用户可以方便地找到优质的服务。 本文源自：金融界 作者：行情君 ...